Zogenix Inc. (NASDAQ:ZGNX) won approval to sell the first painkiller made of pure hydrocodone as U.S. regulators recommended restrictions on popular combination treatments with the drug. The decision helped Zogenix shares climb the most in eight months. Zogenix, Inc. (NASDAQ:ZGNX) shares after opening at $2.82 moved to $2.83 on last trade day and at the end of the day closed at $2.56. Company price to sales ratio in past twelve months was calculated as 10.82 and price to cash ratio as 4.96. Zogenix, Inc. (NASDAQ:ZGNX) showed a negative weekly performance of -6.23%.
Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) recently signed a strategic co-production partnership deal with Patheon. As per the partnership agreement, Exparel will be manufactured and packaged at Patheon’s facility in the U.K. Further, Patheon will construct the dedicated manufacturing suites, install and validate the manufacturing equipments and manufacture Exparel. Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) shares fell -8.11% in last trading session and ended the day on $66.97. PCRX return on equity ratio is recorded as -158.90% and its return on assets is -49.40%. Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) yearly performance is 128.57%.
Raptor Pharmaceutical Corp. logo Raptor Pharmaceutical Corp. (NASDAQ:RPTP) Director Vijay Samant sold 5,000 shares of the stock on the open market in a transaction that occurred on Monday, April 7th. Raptor Pharmaceutical Corp. (NASDAQ:RPTP) shares moved down -7.38% in last trading session and was closed at $8.28, while trading in range of $8.23 – $9.02. Raptor Pharmaceutical Corp. (NASDAQ:RPTP) year to date (YTD) performance is -36.41%.
Retrophin, Inc. (NASDAQ:RTRX) on 27 march reported its financial results for the year ended December 31, 2013. Retrophin Inc. (NASDAQ:RTRX) weekly performance is -13.55%. On last trading day company shares ended up $18.25. Retrophin Inc. (NASDAQ:RTRX) distance from 50-day simple moving average (SMA50) is 7.59%. Analysts mean target price for the company is $51.00.